Personalized mRNA vaccine for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a personalized mRNA vaccine (RH125) designed to train your immune system to attack your cancer. It is for people with advanced solid tumors that have not responded to standard treatments, and it aims to see if the vaccine is safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your tumor must have grown despite standard treatment, or you cannot or will not take standard treatment.
- You need to have at least one measurable tumor and be willing to provide a fresh biopsy sample.
- You should be in reasonably good health (able to do daily activities) and expected to live at least 6 more months.
- Your blood counts, liver, kidney, and heart function must be within acceptable ranges, with no serious infections like active hepatitis B, C, or HIV.
- You must agree to use effective contraception during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine made from your tumor's unique markers (neoantigens) to train your immune system to fight cancer. It is for people with advanced solid tumors who have not had gene therapy and are healthy enough for the vaccine.
This trial tests a personalized vaccine made from unique markers on your tumor cells (called neoantigens). The goal is to help your immune system fight the cancer more effectively. It is for people with advanced solid tumors who have not had gene therapy and are otherwise relatively healthy.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help your body fight advanced cancer. It is for people whose cancer has not responded to other treatments.
This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
This trial tests a personalized mRNA vaccine (InnoPCV) designed from your own tumor's genetic profile to train your immune system to fight advanced solid tumors. It is for people who have not had tumor vaccines or CAR-T therapy before and can provide a tumor sample for customized vaccine creation.
Hear when a new Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.